Roth Capital Reiterates Buy Rating on The Medicines Company (MDCO)
Tweet Send to a Friend
Roth Capital analyst Yasmeen Rahimi reiterated a Buy rating and $72.00 price target on The Medicines Company (NASDAQ: MDCO).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


